NDAINJECTIONINJECTABLE
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPRAM (doxapram hydrochloride) is a small-molecule respiratory stimulant administered via injection used to treat respiratory depression and apnea. It works as a central nervous system stimulant to enhance respiratory drive in patients with inadequate breathing.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial team focus likely shifting toward cost defense and niche positioning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DOPRAM offers limited career growth opportunity due to its mature lifecycle status and approaching loss of exclusivity. Professionals joining this product team should expect defensive, maintenance-focused roles rather than expansion or innovation-driven positions.
Brand ManagerMedical Science Liaison
Worked on DOPRAM at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.